Company

CSL Limited

Headquarters: Parkville, VIC, Australia

Founded: 1916

Employees: 25,000

CEO: Mr. Paul R. Perreault B.A.

show_chart ASX: CSL

Market Cap

A$119.58 Billion

AUD as of April 1, 2022

US$89.69 Billion

history Market Cap History

Company Description

CSL Limited is a biotechnology company providing products to treat and prevent serious human medical conditions. CSL is involved in the research, development, manufacturing, and marketing of a wide range of products including blood plasma derivatives, vaccines, antivenom, and cell culture reagents for medical and genetic research and manufacturing applications.

CSL Limited market capitalization over time

Evolution of CSL Limited market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of CSL Limited

Detailed Description

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

Wikipedia Introduction

CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications.

Source: Wikipedia, retrieved on March 31, 2022, 8:57 p.m.

Stocks & Indices

CSL Limited has the following listings and related stock indices.


Stock: ASX: CSL

Stock: FSX: CSJ

Best-Selling Downloads - Australia

ASX 200 Companies Excel Download $19.90
All Ordinaries Companies Excel Download $39.90
580 Unicorn Startup Companies – Excel Spreadsheet $29.90

Save tens of hours in 2 minutes!

Product & Services

blood plasma, vaccines, antivenom, other laboratory and medical products

Key People

Paul Perreault (CEO)

Financials

Revenue: AUD$10.61 billion (2021)

Net income: USD$1.919 billion (2019)

Details

Headquarters:

45 Poplar Road

Parkville, VIC 3052

Australia

Phone: 61 3 9389 1911

Fax: 61 3 9389 1434